SCHEDULE 13G: Sanofi Discloses 9.05% Stake in Innate Pharma SA

Sanofi has filed a Schedule 13G, revealing a beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares.

Summary

• Sanofi, a French pharmaceutical company, has reported beneficial ownership of 8,345,387 ordinary shares of Innate Pharma SA.
• This stake represents 9.05% of Innate Pharma SA's outstanding ordinary shares.
• The percentage is calculated based on 92,175,723 ordinary shares outstanding (excluding treasury shares) as of April 25, 2025, as reported by Innate Pharma SA.
• Sanofi holds sole voting and sole dispositive power over all 8,345,387 shares.
• The shares are held of record by Sanofi-Aventis Participations SAS, which is an indirect, wholly-owned subsidiary of Sanofi.
• Sanofi certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Innate Pharma SA, nor in connection with any transaction having that purpose or effect, other than activities solely related to nominations under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A major pharmaceutical company like Sanofi holding a significant stake in Innate Pharma SA can be seen as a vote of confidence and may imply future strategic collaboration, even if control is not the stated intent. There are no explicit negative financial or operational details in this disclosure.

Positives

• A significant stake by a major pharmaceutical company like Sanofi could be viewed positively, potentially indicating a strategic interest or confidence in Innate Pharma SA's pipeline or technology.
• The continued holding of a substantial stake by Sanofi may suggest stability and a long-term relationship between the two companies, which could be beneficial for Innate Pharma SA.

Risks

• The certification by Sanofi that the shares are not held for the purpose of changing or influencing control of Innate Pharma SA means that a potential takeover or significant strategic shift driven by Sanofi is not the intent behind this holding, which might disappoint investors hoping for such an event.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Innate Pharma SA's business operations or financial performance. Sanofi's certification indicates that its intent is not to influence or change control of the issuer.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Alexandra Roger, Head of Securities Law and Capital Markets for Sanofi)

Industry Context

This filing highlights a significant equity stake by a global pharmaceutical giant, Sanofi, in a smaller biotechnology company, Innate Pharma SA. Such investments are common in the pharmaceutical industry, often preceding or accompanying strategic collaborations, licensing agreements, or joint ventures, as larger companies seek to access innovative pipelines or technologies from smaller, agile biotechs. While this 13G filing itself does not detail the strategic rationale, the substantial ownership suggests a vested interest beyond a mere passive investment.

Comparison to Industry Standards

• While this document is an ownership disclosure rather than a performance report, Sanofi's 9.05% stake in Innate Pharma SA is a notable minority investment. In the pharmaceutical and biotechnology sectors, strategic equity investments by large pharma companies into smaller biotechs are a common mechanism for fostering partnerships, accessing early-stage research, or securing future product rights. For example, similar strategic investments have been seen with companies like Bristol Myers Squibb's stake in Dragonfly Therapeutics or Pfizer's various equity investments in emerging biotechs, often preceding or accompanying broader collaboration agreements. The size of this stake is significant enough to suggest a strategic relationship, even if not for control, differentiating it from purely passive institutional investments which typically remain below such thresholds or are held by diverse funds.

Related Party Transactions

• The shares are held of record by Sanofi-Aventis Participations SAS, which is identified as the reporting person's (Sanofi's) indirect, wholly-owned subsidiary. This indicates an intra-company transaction structure for holding the shares.

Stakeholder Impact

• **Shareholders of Innate Pharma SA**: May view Sanofi's significant stake as a positive signal, potentially indicating stability, future collaboration opportunities, or validation of Innate Pharma's assets, which could positively influence share price.
• **Management of Innate Pharma SA**: The presence of a major shareholder like Sanofi, even without intent to control, could influence strategic discussions and future partnerships.
• **Competitors of Innate Pharma SA**: May observe Sanofi's investment as a strategic move, potentially signaling areas of interest or future competitive dynamics in the biotech space.

Key Dates

Keywords

Sanofi, Innate Pharma SA, Schedule 13G, Beneficial Ownership, Pharmaceutical, Biotechnology, Equity Stake, SEC Filing, Investment, Shareholding